Umecrine Mood’s candidate drug UC1010 is a first‐in‐class therapy for PMDD. UC1010 has been developed specifically to target the atypical effects of progesterone metabolites on GABA-A receptor activity in the brain, believed to underlie key PMDD symptoms.
In an exploratory double blind, randomized multicenter study, 120 patients with PMDD received placebo or one of two doses of UC1010 during one menstrual cycle. The objectives of the trial were to study the safety and efficacy of UC1010. The primary efficacy end‐point was assessed using a validated daily rating scale (DRSP), to measure the average late luteal phase symptoms in patients treated with UC1010 vs. those given placebo. As previously reported, the primary efficacy end-point of the study was not met.
Following final analysis of the study data, we report here that UC1010 elicits a highly statistically significant reduction of symptoms in PMDD patients that have taken the drug according to the intended treatment regimen. The post‐hoc analysis revealed two key variables that impacted the study outcome:
1. Despite patient randomization, the baseline follicular phase symptoms showed a skewed distribution between study groups. Recalculation of results to correct for individual follicular symptoms reveals a statistically significant improvement of symptoms by UC1010 compared to placebo in the total study population (p<0.05 for the total premenstrual symptom score).
2. More significantly, due to inconsistencies in the assessment of ovulation, 32% of patients did not receive treatment as intended according to the protocol. Inclusion only of patients treated as intended shows there were highly significant beneficial effects of UC1010 (both doses) compared to placebo, both for the cardinal PMDD symptoms (p=0.003) and total premenstrual symptom scores (p=0.006) as well as for the impairment score (p=0.01), which specifically measures the impact of symptoms on daily life in the week prior to menstruation.
There were no safety concerns with UC1010 and it was well tolerated.
Marie Bixo, Principle Investigator, said: “These results are very encouraging and well in line with effects seen in other studies (using antidepressants), with the added bonus that UC1010 is safe and well tolerated, with none of the sideeffects seen with other agents used for PMDD treatment”.
Karin Ekberg, CEO of Umecrine Mood, commented: “This exploratory Phase I/II trial is the first to show a beneficial effect of a novel mechanism‐based therapy to treat a condition affecting a large proportion of women. We have learned some important lessons from this initial study and are now well‐positioned to move forward to conduct a definitive Phase II clinical trial”.
For further information, please contact:
Karin Ekberg, CEO,
Umecrine Mood AB
Phone: +46 8 524 844 82, e‐mail: